Xenitra Expands Healthcare Reach with A$5 Million FSMP Procurement Deal

Xenitra Diversifies Healthcare Portfolio with FSMP Deal

Xenitra Limited (ASX:XEN) has secured a three-year Framework Purchase Agreement worth A$5 million through its Hong Kong subsidiary, Fukang, targeting Food for Special Medical Purposes (FSMP) products. This deal with JOY CHARM LIMITED marks a strategic pivot beyond the company’s traditional over-the-counter (OTC) medicines into the specialised medical nutrition segment, leveraging existing regulatory and commercial infrastructure established by the recent Fukang acquisition.

Under the agreement effective from August 2026 to August 2029, procurement specifics, including product types, quantities, and pricing, will be arranged via individual purchase orders contributing to the aggregate target. While the A$5 million figure is a target rather than a guaranteed minimum, it represents a meaningful addition to Xenitra’s healthcare pipeline alongside its recent A$12 million pharmaceutical procurement deal with Kangsheng, further cementing its presence in China’s healthcare distribution landscape.

Commercial Momentum and Payment Structure

Fukang’s integration into Xenitra’s operations has already yielded tangible results, with sales surpassing A$450,000 in July alone. This strong start complements the new agreements and highlights the potential of the combined platform. The payment terms are designed to support healthy cash flow dynamics, requiring 20% payment shortly after purchase order execution and invoice receipt, with the remaining 80% payable upon delivery documentation. This mirrors existing terms in Xenitra’s OTC medicines division, ensuring operational consistency across its healthcare segments.

Tapping into China’s Rapidly Growing FSMP Market

The FSMP market in China is expanding at an annualised rate exceeding 25%, ballooning from RMB7 billion (approximately A$1.5 billion) in 2020 to RMB23 billion (A$4.8 billion) in 2024. Regulatory changes, including the removal of import tariffs on FSMP products for consumers over three years old, have further stimulated demand, particularly for imported specialised nutrition products. This regulatory environment, combined with growing consumer awareness, positions Xenitra well to capitalise on these trends through its Fukang subsidiary.

Alongside FSMPs, China’s OTC medicines market remains robust, valued at around RMB400 billion in 2023 and growing at roughly 9% annually. OTC products account for nearly half of retail pharmacy medicine sales, with online pharmacy channels offering additional growth avenues under established regulatory frameworks. Xenitra’s dual focus on OTC and specialised nutrition allows it to address significant segments within China’s evolving healthcare ecosystem.

Strategic Implications for Xenitra’s Growth

Non-Executive Chairman Dr Anthony Noble emphasised the agreement’s role in broadening Xenitra’s commercial reach beyond conventional OTC medicines. He highlighted the untapped potential in pharmaceutical markets accessible through Fukang, alongside the company’s Nutritionals and OPAL tokenised sales platforms, all contributing to a diversified revenue base. The company’s ability to integrate blockchain-enabled tokenised distribution channels further differentiates its approach in a competitive market.

With multiple procurement agreements now in place and initial sales momentum established, Xenitra appears poised to deepen its foothold in China’s healthcare sector. The execution of individual purchase orders under this FSMP framework will be a key metric to watch as the company progresses through FY27.